GLP-1 RAs have high glucose-lowering efficacy, but with variation within the drug class
[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C
Insurance limitations and cost barriers also drive patients toward combination thinking
If you're a candidate, your medication is shipped discreetly to your door
The Hypothalamic-Pituitary-Ovarian Axis, Ovarian Disorders, and Brain Aging
The ADA 2025 presentations will cover: Phase 1 Trial Results for HM15275, Robust anti-obesity effect and mechanistic insights of HM15275 in animal models of obesity, Mechanistic insights into HM15275s improved quality of weight loss compared to tirzepatide (Zepbound), Weight loss and differentiated body composition improvement effects of HM17321, Glycemic control improvement observed with HM17321, and Synergistic effects on body composition improvement when combining HM15275 and HM17321 A large delegation from Hanmis R&D Center will attend ADA 2025 to present poster sessions showcasing the companys novel therapeutic approaches in obesity treatment and to explore potential collaborations with leading global pharmaceutical companies
